James Paul Lang
James Paul Lang's purchase track record
James Paul Lang has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/14/2025 | OPRX | $2.44M | +83.7% | +123.0% | +16.8% |
| 8/19/2022 | OPRX | $99K | +29.3% | +12.6% | -3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Halozyme Adds Jim Daly to Board Amid Q2 Earnings Review. Halozyme Therapeutics has appointed Jim Daly to its Board of Directors, a move that signals continued focus on governance and long-term strategy. This update arrives alongside a broader market review of the company's Q2 performance relative to other therapeutics firms. The stock is currently trading above its average analyst target price, with recent technical data showing confirmation near key support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
BioVie Featured on Bloomberg Television Segment. BioVie was included in a new episode of The Street Show airing on Bloomberg Television. The segment also featured Glint, Sagtec Global, and SafeSpace Global. This media appearance provides additional visibility for the company to a financial audience.
Transaction History
| OPRX | ▲ Buy | Grant | 34,517 | $0 | 6/9/2026 | View on chart |
| HALO | ▲ Buy | Grant | 3,796 | $0 | 5/5/2026 | View on chart |
| HALO | ▲ Buy | Grant | 889 | $0 | 1/2/2026 | View on chart |
| OPRX | ▲ Buy | Grant | 9,868 | $0 | 6/11/2025 | View on chart |
| OPRX | ▲ Buy | Open Market | 321,408 | $2.4M | 3/14/2025 | View on chart |
| OPRX | ▲ Buy | Grant | 13,286 | $0 | 6/7/2024 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 10,061 | $0 | 6/5/2024 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 4,637 | $0 | 6/7/2023 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 657 | $0 | 3/30/2023 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 409 | $0 | 12/30/2022 | View on chart |
| BIVI | ▲ Buy | Grant | 43,578 | $0 | 11/23/2022 | View on chart |
| OPRX | ▲ Buy | Option Exercise | 334 | $0 | 9/29/2022 | View on chart |
| OPRX | ▲ Buy | Open Market | 6,000 | $99K | 8/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
OptimizeRx Expands Ad Reach via OpenPath Deal with The Trade Desk
OptimizeRx has announced a partnership with The Trade Desk that uses its OpenPath platform to add authenticated healthcare professional reach to the ad network. The deal is expected to broaden the company’s inventory and provide advertisers with more precise targeting in the healthcare space. This collaboration follows a series of moves to grow OptimizeRx’s presence in the digital advertising market.
OptimizeRx Expands Ad Reach via OpenPath Deal with The Trade Desk. OptimizeRx has announced a partnership with The Trade Desk that uses its OpenPath platform to add authenticated healthcare professional reach to the ad network. The deal is expected to broaden the company’s inventory and provide advertisers with more precise targeting in the healthcare space. This collaboration follows a series of moves to grow OptimizeRx’s presence in the digital advertising market.